Raptor Pharmaceutical Inc.'s PROCYSBI™ Receives Positive Recommendation From CHMP

Published: Jun 28, 2013

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

NOVATO, Calif., June 28, 2013 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced today that the European Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending marketing authorization for PROCYSBI™ 25mg and 75mg gastro-resistant hard capsules, cysteamine (as mercaptamine bitartrate) for the treatment of proven nephropathic cystinosis. If approved, PROCYSBI will be indicated for the treatment of proven nephropathic cystinosis.

Help employers find you! Check out all the jobs and post your resume.

Back to news